# A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

> **NCT03231878** · PHASE2,PHASE3 · COMPLETED · sponsor: **Minoryx Therapeutics, S.L.** · enrollment: 105 (actual)

## Conditions studied

- Adrenoleukodystrophy

## Interventions

- **DRUG:** MIN-102
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03231878
- **Lead sponsor:** Minoryx Therapeutics, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2021-06-25
- **Final completion:** 2025-03-06
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03231878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03231878, "A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03231878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*